HER2 Heterogeneity Scoring for Tumor Therapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods fail to accurately account for HER2 heterogeneity in tumors, leading to inaccurate predictions of responsiveness to HER2-directed therapies due to intratumoral heterogeneity and differences in HER2 expression patterns between breast and gastric cancers.
Innovation Solution
Assessing HER2 heterogeneity by scoring HER2 protein and RNA status using specific biomarker reagents and nucleic acid probes, categorizing samples into groups A to F based on differing scores in distinct foci or invasive regions, to predict responsiveness to HER2-directed therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing methods are used to evaluate HER2 status, then the evaluation process is simple, but the prediction accuracy of tumor responsiveness to HER2-directed therapies is insufficient due to failure to account for HER2 heterogeneity
Solution Approach 1:
The tumor sample is divided into multiple distinct foci or regions (first foci, second foci, invasive regions, non-invasive regions) and each region is evaluated separately for HER2 status. This segmentation allows detection of heterogeneity within the tumor by comparing HER2 expression patterns across different spatial locations, thereby improving prediction accuracy while managing evaluation complexity through systematic regional assessment.
Solution Approach 2:
Different regions of the tumor are assessed for their specific HER2 expression characteristics (HER2 protein-positive, HER2 RNA-positive, HER2 gene amplification). The evaluation recognizes that different foci may have different HER2 statuses and uses this local quality information to predict treatment responsiveness more accurately, rather than treating the entire tumor as homogeneous.
2Adaptability or versatility
If HER2 status is evaluated using a single uniform method, then the evaluation process is straightforward, but it fails to capture intratumoral heterogeneity and differences between breast and gastric cancers
Solution Approach 1:
The evaluation method is designed to be universally applicable to multiple cancer types (breast cancer, gastric cancer, gastroesophageal junction cancer) by assessing the same HER2 parameters (protein, RNA, gene amplification) across different tumor foci. The method adapts to different cancer types by applying the multi-parameter assessment framework, capturing both intratumoral heterogeneity and inter-cancer type differences without requiring fundamentally different approaches for each cancer type.
3Measurement precision
If only HER2 protein expression is assessed, then the assessment is simple, but it misses important information about HER2 RNA and gene amplification status that contribute to treatment response prediction
Solution Approach 1:
The method combines three different types of HER2 assessments (protein expression by IHC, RNA status by ISH, and gene amplification by FISH) into a unified evaluation framework. By merging these complementary assays and integrating their results across multiple foci, the method achieves comprehensive HER2 status characterization that improves treatment response prediction while managing the inherent complexity through systematic integration of multiple data types.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the accuracy of predicting tumor responsiveness to HER2-directed therapies by identifying HER2-positive sub-populations, particularly in gastric cancer, improving treatment efficacy.
Implementation Method 1
contacting a sample of the tumor with a biomarker-specific reagent that specifically binds to HER2 protein and detecting HER2 protein in the sample
Implementation Method 2
contacting the sample of the tumor with a nucleic acid probe that specifically binds HER2 RNA and detecting HER2 RNA status in the sample
Data Source
AI summary
A method for predicting responsiveness to a HER2-directed therapy by assessing HER2 heterogeneity in a tumor includes contacting a sample of the tumor with a biomarker-specific reagent that specifically binds to HER2 protein and detecting HER2 protein in the sample, contacting the sample of the tumor with a first nucleic acid probe that specifically binds HER2 genomic DNA and detecting HER2 gene amplification status in the sample, contacting the sample of the tumor with a second nucleic acid probe that specifically binds HER2 RNA and detecting HER2 RNA status in the sample scoring the HER2 protein (IHC), HER2 gene (DISH), and HER2 RNA (RNA-ISH), predicting that the tumor is responsive to the HER2-directed therapy if the tumor reveals a first foci having a first score and a second score, in which the first score and the second score are not the same.